ReviewCureus2025
Artificial Intelligence in Rheumatology: Clinical Applications in Rheumatoid Arthritis, Osteoarthritis, and Systemic Lupus Erythematosus.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High Patient Willingness to Grant Broad Consent for Real-World Data Use in Rheumatology-Implications for Real-World Data Platform Governance: Cross-Sectional Study.Journal of medical Internet research · 2026Article
- Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) has emerged as a transformative force in rheumatology, offering novel diagnostic, predictive, and therapeutic capabilities across chronic inflammatory and autoimmune diseases. This narrative review specifically focuses on rheumatoid arthritis (RA), osteoarthritis (OA), and systemic lupus erythematosus (SLE), where AI applications have been most extensively studied and show the greatest clinical translational potential. In RA, AI applications span early diagnosis via imaging-based models, identification of novel biomarkers through multi-omics integration, and prediction of disease progression and therapeutic response using deep learning algorithms. For OA, AI enhances radiographic interpretation, develops personalized risk prediction models, and enables individualized rehabilitation through wearable and biomechanical data analysis. In SLE, AI aids in biomarker discovery, disease activity monitoring via biosensors, and flare prediction using federated machine learning, with promising applications in high-risk groups. Despite these advances, challenges persist regarding data quality, algorithmic bias, limited explainability, and lack of real-world validation. Ethical considerations surrounding data privacy and equitable access must be addressed to ensure responsible deployment. The review underscores the importance of hybrid human-AI collaboration, integration into electronic health records, and interdisciplinary cooperation to unlock AI's full clinical potential. Moving forward, research must prioritize transparency, regulatory standardization, and equitable implementation to enhance personalized care in rheumatology. This review consolidates current evidence, highlights key innovations, and identifies future directions essential for advancing AI-driven rheumatologic care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.